ORCID as entered in ROS

Select Publications
2023, 'The role of nutrition in inflammatory bowel disease: Disease associations, management of active disease and maintenance of remission', in Encyclopedia of Human Nutrition Volume 1 4 Fourth Edition, pp. 669 - 697, http://dx.doi.org/10.1016/B978-0-12-821848-8.00104-9
,2025, 'Comparing Long-Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern', Journal of Gastroenterology and Hepatology Australia, 40, pp. 1174 - 1181, http://dx.doi.org/10.1111/jgh.16916
,2025, 'DOP015 Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s Program', Journal of Crohn's and Colitis, 19, pp. i111 - i112, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0054
,2025, 'N26 Factors associated with Inflammatory Bowel Disease (IBD) helpline (HL) utilisation: Crohn’s Colitis Cure Data Insight’s Program', Journal of Crohn's and Colitis, 19, pp. i2481 - i2482, http://dx.doi.org/10.1093/ecco-jcc/jjae190.1558
,2025, 'P0018 Fat rich dietary habits: Further increasing IBD risk in first degree relatives', Journal of Crohn's and Colitis, 19, pp. i358 - i358, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0192
,2025, 'P0161 The primary sclerosing cholangitis and ulcerative colitis colonic mucosa defined through paired microbial and single-cell RNA sequencing', Journal of Crohn's and Colitis, 19, pp. i557 - i557, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0335
,2025, 'P0203 Unique faecal & oral microbiota signatures in first degree relatives of inflammatory bowel disease patients', Journal of Crohn's and Colitis, 19, pp. i607 - i607, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0377
,2025, 'P0257 Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial', Journal of Crohn's and Colitis, 19, pp. i689 - i690, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0431
,2025, 'P0603 The real-world use of intravenous and subcutaneous Vedolizumab in IBD across Australia and New Zealand, Crohn’s Colitis Cure Data Insight’s Program', Journal of Crohn's and Colitis, 19, pp. i1197 - i1198, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0777
,2025, 'P0660 Comparative Accuracy and Reliability of Handheld versus Cart-Based Ultrasound in assessing Inflammatory Bowel Disease Activity', Journal of Crohn's and Colitis, 19, pp. i1290 - i1292, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0834
,2025, 'P0754 Extensive disease clearance as a novel composite endpoint to predict long-term relapse in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial', Journal of Crohn's and Colitis, 19, pp. i1453 - i1454, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0928
,2025, 'P0759 The interplay between dietary intake and disease activity in Australian adults with and without Inflammatory Bowel Disease', Journal of Crohn's and Colitis, 19, pp. i1465 - i1465, http://dx.doi.org/10.1093/ecco-jcc/jjae190.0933
,2025, 'P1132 Patterns and predictors of steroid use in people with IBD in routine care across ANZ', Journal of Crohn's and Colitis, 19, pp. i2073 - i2073, http://dx.doi.org/10.1093/ecco-jcc/jjae190.1306
,2025, 'P1281 Active perianal fistulising Crohn’s Disease is associated with a higher burden of psychological distress, depression, anxiety, stress and opioid use', Journal of Crohn's and Colitis, 19, pp. i2311 - i2312, http://dx.doi.org/10.1093/ecco-jcc/jjae190.1455
,2025, 'P1327 Microbial signatures associated with Inflammatory Bowel Disease in Australia: baseline data from the Australian IBD Microbiome study', Journal of Crohn's and Colitis, 19, pp. i2388 - i2389, http://dx.doi.org/10.1093/ecco-jcc/jjae190.1501
,2025, 'P1340 Gut microbiota changes are associated with type of advanced therapy in patients with Inflammatory Bowel Disease: baseline data from the Australian IBD Microbiome study', Journal of Crohn's and Colitis, 19, pp. i2410 - i2412, http://dx.doi.org/10.1093/ecco-jcc/jjae190.1514
,2025, 'P1344 Impaired health-related quality of life is associated with alterations in gut microbiota signatures in patients with Inflammatory Bowel Disease: baseline data from the Australian IBD Microbiome study', Journal of Crohn's and Colitis, 19, pp. i2419 - i2421, http://dx.doi.org/10.1093/ecco-jcc/jjae190.1518
,2025, 'P1345 Association of gut microbiota changes and disease activity in patients with Crohn’s disease and ulcerative colitis: baseline data from the Australian IBD Microbiome study', Journal of Crohn's and Colitis, 19, pp. i2422 - i2423, http://dx.doi.org/10.1093/ecco-jcc/jjae190.1519
,2025, 'Epidemiology and Treatment Patterns of Fistulizing Crohn's Disease in a Large, Real-World Australasian Cohort', Gastro Hep Advances, 4, http://dx.doi.org/10.1016/j.gastha.2024.100594
,2025, 'Ileal ulceration and haematochezia in an 83-year old', Frontline Gastroenterology, http://dx.doi.org/10.1136/flgastro-2025-103067
,2024, 'Dietary Patterns and Fibre Intake Are Associated with Disease Activity in Australian Adults with Inflammatory Bowel Disease: An Exploratory Dietary Pattern Analysis †', Nutrients, 16, http://dx.doi.org/10.3390/nu16244349
,2024, 'Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial', Clinical Gastroenterology and Hepatology, 22, pp. 2299 - 2308.e5, http://dx.doi.org/10.1016/j.cgh.2024.04.019
,2024, 'Dietary Determinants of Metabolic and Gut Microbial Health in Patients with Inflammatory Bowel Disease', Nutrients, 16, http://dx.doi.org/10.3390/nu16193233
,2024, 'Dietary Emulsifier Exposure in People with Inflammatory Bowel Disease Compared with Healthy Controls: Is There a Cause for Concern?', Inflammatory Bowel Diseases, 30, pp. 1241 - 1250, http://dx.doi.org/10.1093/ibd/izad318
,2024, 'P1005 Dose escalated Infliximab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1809 - i1809, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1135
,2024, 'P1012 Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1820 - i1820, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1142
,2024, 'P1030 Inflammatory Bowel Disease helpline contact trends in a real-world Australasian cohort: Crohn’s Colitis Cure (CCC) data insight’s program', Journal of Crohn's and Colitis, 18, pp. i1849 - i1850, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1160
,2024, 'P1129 Fistulising Crohn's Disease in a large Australasian cohort - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i2010 - i2010, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1259
,2024, 'P1233 Serum insulin is associated with c-reactive protein and gut microbial diversity in inflammatory bowel disease', Journal of Crohn's and Colitis, 18, pp. i2171 - i2171, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1363
,2024, 'P286 Variation of outcomes in inflammatory bowel disease at ten Australasian centres - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i650 - i650, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0416
,2024, 'P462 The burden of mental health disease in people with inflammatory bowel disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i923 - i923, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0592
,2024, 'P880 The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s program', Journal of Crohn's and Colitis, 18, pp. i1612 - i1613, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1010
,2024, 'P959 Dose escalated vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1732 - i1732, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1089
,2024, 'High Technical Success Rate of Endoscopic Balloon Dilatation Reduces Surgical Requirement for Patients With Stricturing Crohn’s Disease', GastroHep, 2024, http://dx.doi.org/10.1155/2024/3686618
,2024, 'Mo1833 DOSE ESCALATED USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)03072-5
,2024, 'Mo1834 DOSE ESCALATED VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 1135, http://dx.doi.org/10.1016/s0016-5085(24)03073-7
,2024, 'Mo1835 DOSE ESCALATED INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 1135, http://dx.doi.org/10.1016/s0016-5085(24)03074-9
,2024, 'Su1841 VARIATION IN OUTCOMES IN INFLAMMATORY BOWEL DISEASE AT TEN AUSTRALASIAN CENTRES - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 839, http://dx.doi.org/10.1016/s0016-5085(24)02405-3
,2024, 'Su1874 THE BURDEN OF MENTAL HEALTH DISEASE IN PEOPLE WITH INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)02438-7
,2024, 'Tu1891 THE REAL-WORLD USE OF FIVE-AMINOSALICYLATE (5ASA) TREATMENT FOR ULCERATIVE COLITIS IN AUSTRALIA AND NEW ZEALAND: CROHN'S COLITIS CURE (CCC) DATA INSIGHT'S PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)03792-2
,2023, 'P413 Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial', Journal of Crohn's and Colitis, 17, pp. i542 - i543, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0543
,2023, 'P523 Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn’s Colitis Care (CCCare): A real world observational study.', Journal of Crohn's and Colitis, 17, pp. i650 - i651, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0653
,2023, 'P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort', Journal of Crohn's and Colitis, 17, pp. i793 - i794, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0793
,2023, 'P753 Comparing long-term outcomes in inflammatory bowel disease patients between switch and non-switch cohorts: no differences in infliximab persistence or safety outcomes after 54 months', Journal of Crohn's and Colitis, 17, pp. i884 - i885, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0883
,2023, '1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL', Gastroenterology, 164, pp. S - 221, http://dx.doi.org/10.1016/s0016-5085(23)01488-9
,2023, 'Su1782 QUALITY, SAFETY AND EQUITY OF CARE OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS AT FOUR AUSTRALIAN TERTIARY REFERRAL CENTRES USING THE CLOUD-BASED MANAGEMENT SYSTEM CROHN'S COLITIS CARE (CCCARE) : A REAL WORLD OBSERVATIONAL STUDY', Gastroenterology, 164, pp. S - 679, http://dx.doi.org/10.1016/s0016-5085(23)02580-5
,2022, 'Type 2 autoimmune pancreatitis associated with severe ulcerative colitis: Three case reports', World Journal of Clinical Cases, 10, pp. 8788 - 8796, http://dx.doi.org/10.12998/wjcc.v10.i24.8788
,2022, 'Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease', World Journal of Gastroenterology, 28, pp. 2597 - 2608, http://dx.doi.org/10.3748/wjg.v28.i23.2597
,2022, 'Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial', Lancet Gastroenterology and Hepatology, 7, pp. 141 - 151, http://dx.doi.org/10.1016/S2468-1253(21)00400-3
,2021, 'Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study)', JOURNAL OF CROHNS & COLITIS, 15, pp. S029 - S029, http://dx.doi.org/10.1093/ecco-jcc/jjab075.029
,